Novo Nordisk’s science chief followed last week’s FDA panel meeting via live cast along with hundreds of Novo employees, and it was a much more pleasant experience than on the two previous occasions. Find out why the CSO is so sure the company will make it big on the US obesity market.
Following the reinforcement of the company’s financial foundation, Genmab’s CEO will now implement a much more commercial mindset in all aspects of drug development and the company will possibly begin to market drugs on its own.
FDA has already rejected Genzyme’s MS drug Lemtrada once, but the company’s executives in charge of the MS area believe in approval second time around. Major bank Barclays is less optimistic. A new verdict is expected to fall before the close of 2014.
Many people dream of it, but few have actually tried it in Denmark – selling something to Big Pharma. There is one crucial factor if you want to increase your chances, says Allan Jensen, who has worked for the Danish biotech company Symphogen and the US drug giant Pfizer.
The FDA has revealed the agenda for Thursday’s panel meeting to discuss Novo Nordisk's candidate drug to treat obesity. There are no major surprises, says an analyst, who identifies the biggest obstacle for approval of the potential blockbuster.
According to a sector analyst, gene analysis company Exiqon finds itself in difficult times and there is no light at the end of the tunnel this year, as the company will struggle to meet its full-year guidance.
Nordea believes that Novo Nordisk is heading into an easier second half of the year in which the major event will be an FDA decision on the Danish group’s obesity contender – a decision that should go Novo’s way, the bank says.
Novo Nordisk CSO Mads Krogsgaard Thomsen admits that it has been more difficult than expected to deliver within the now abandoned inflammation unit. The company’s four attempts all missed the target and the alternative to abandoning the entire project would have been a major acquisition.
The biggest acquisition in the history of the company led to Eli Lilly’s intense focus on oncology drugs, which is now nearing its climax. The US company’s Scandinavian head has talked to MedWatch about the crown jewel of the group’s pipeline and the ubiquitous presence of a certain rival.
Danish diabetes giant Novo Nordisk has chosen to discontinue all its R&D activities within inflammatory disorders to focus fully on the discovery and development of diabetes drugs. The closure affects 400 employees.
Although the recently placed Canadian vaccine order is unlikely to lead to dramatic top line growth for Bavarian Nordic, the order is a significant strategic step toward the end goal, the company’s CFO says.
Lundbeck’s blockbuster candidate, antidepressant Brintellix, is likely to be given general conditional reimbursement. The recommendation from the Danish Reimbursement Committee is in line with Lundbeck’s own expectations, says the director of Lundbeck Pharma Denmark.
Ambu has work to do in Q4 of its fiscal year 2013/2014 if it is to live up to its full year guidance. CEO Lars Marcher says it is all about the trend, which has looked quite solid in the last two quarters.
Financial news were few and far between from Zealand Pharma in the latest quarter, but the clinical programs are developing according to plan, says CEO David Solomon, who also comments on the recent sale of Santaris.
An employee’s level of commitment can be affected by circumstances in the family, such as disease – and the company should be sensitive to that. But if people are down-right uncommitted, the corporate culture is so strong that it will gradually expel them. Lars Rebien, at the peak of his career, spoke to Medwatch about the unique Novo spirit, about failing politicians, and about growing softer.
Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.